Campath-1H + FK506 and Methylprednisolone for GVHD
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor
Interventions: BIOLOGICAL: alemtuzumab|DRUG: methylprednisolone|DRUG: tacrolimus
Sponsor: Case Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)